NIH launches phase 3 investigational trials for pair of monoclonal antibody therapies for COVID-19

Dec 18, 2020 - 02:36 PM
NIH-cancer-deaths

The National Institutes of Health yesterday announced enrollment in phase 3 of the clinical trial of two disparate therapies. This trial is specifically looking at the safety and effectiveness of the therapeutics in people hospitalized with moderate COVID-19 symptoms.

The two approaches being tested are the use of VIR-7831, a monoclonal antibody developed through a partnership between GlaxoSmithKline and Vir Biotechnology, Inc., and a combination of neutralizing monoclonal antibodies, BRII-196 and BRII-198, that are manufactured by Brii Biosciences.

Initially, approximately 450 people will be enrolled, with a third of participants receiving a placebo, a third receiving VIR-7831 and a third getting the combination of Brii therapeutics. It the trials appear successful, an additional 700 people hospitalized with COVID-19 will be enrolled. 

Related News Articles

Headline
HHS seeks feedback on immunization categories in executive order on childhood vaccine schedule
The Department of Health of Human Services Aug. 21 issued a request for information seeking feedback on immunization categories within the Aug. 10 executive…
Headline
CDC reports increase in kindergarten vaccine exemptions
For the 2025-2026 school year, exemptions from one or more vaccines among U.S. kindergartners was at 4.2%, increasing from 3.6% for the previous school year,…
Headline
HHS to end emergency authorization for COVID-19 drugs, medical devices 
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
CDC report highlights low use of COVID-19 antivirals among people 65 and older 
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
CDC report finds COVID-19 vaccine for children reduced chances of ED, urgent care visits
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
ACIP recommends patients consult their provider for COVID-19 vaccine
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…